Dare Bioscience Inc. (DARE)
DARE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.7477
-0.32% on the day
Market cap
$14.7M
Nano cap
Revenue · 2025
$1.0M
+10429.4% on 2024
Net income · 2025
-$13.4M
-1300.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | DARE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001401914 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.0M |
| Net income | -$13.4M |
| Operating income | -$13.6M |
| Net margin | -1300.7% |
| Operating margin | -1315.5% |
| Revenue growth | +10429.4% |
| Cash | $24.7M |
| Total assets | $32.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 14.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-04 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-10-02 |
| Latest proxy | DEF 14A | 2026-10-06 |
Source: SEC EDGAR submissions feed, 776 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PTN | Palatin Technologies Inc. | $8.19 | -4.21% | $14.6M |
| RKTO | Rocket One Inc. | $0.5708 | -4.85% | $14.2M |
| KTTA | Pasithea Therapeutics Corp. | $0.4238 | -5.30% | $14.2M |
| MRKR | Marker Therapeutics Inc. | $0.9249 | -8.43% | $15.4M |
| TVRD | Tvardi Therapeutics Inc. | $1.04 | -1.89% | $13.9M |
| ALLR | Allarity Therapeutics Inc. | $0.8699 | +1.14% | $13.8M |
| HIND | Vyome Holdings Inc. | $1.97 | -1.99% | $13.8M |
| GTBP | GT Biopharma Inc. | $6.50 | -4.41% | $13.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier